Menu
Recruiting NCT06658912

Planning Grant for TOPS for Breast Cancer Survivors

No phase Interventional Breast Cancer Weight Loss

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: TOPS Classes.
Who it may be relevant to
Registry conditions: Breast Cancer, Weight Loss. Basic parameters: 21 years — 90 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Planning Grant for Take Off Pounds Sensibly (TOPS) Classes for Breast Cancer Survivors

Overview

The purpose of this study is to help make a community led weight loss program known as Take Off Pounds Sensibly (TOPS) more relevant for breast cancer survivors. This study is made up to two parts. The first part includes using focus groups to review current materials that the investigators plan to use in upcoming TOPS classes and provide feedback. Focus groups will be made up of women who are breast cancer survivors. The second part includes taking the feedback received from these focus groups and use this feedback to tailor TOPS classes for breast cancer survivors. This ClinicalTrials.gov record is specific to the second part of the study.

Detailed description

The purpose of this study is to help make a community led weight loss program known as Take Off Pounds Sensibly (TOPS) more relevant for breast cancer survivors.

This study is made up to two parts. The first part includes using focus groups to review current materials that the investigators plan to use in upcoming TOPS classes and have the groups provide feedback. Focus groups will be made up of breast cancer survivors that have recruited from local support group chapters. The goal is to recruit approximately 25 people to take part in these focus groups. Meetings of focus groups will be conducted remotely through Zoom and will be recorded. A meeting of the focus group will last anywhere from 60-90 minutes.

The information gathered from these groups will be used to improve the materials which lead to part two of the study.

The second part includes using these materials in TOPS classes that are tailored for breast cancer survivors and determining if the TOPS classes are effective on those who attend the classes. Effectiveness of the class will be determined by the weight loss of the participant and an impact on their heart health.

For the first 6 months, participants will attend dietician-led TOPS sessions conducted virtually through Zoom. Participants' weight will be measured as instructed using a Bluetooth scale that will send their weight measurements back to the team. Participants will also measure their blood pressure through a Bluetooth device provided by the study team.

After 6 months, participants will be asked to join a TOPS chapter in their community. The study team will help them local a chapter that is convenient for them. They must attend these classes for another 6 months. Total time in this portion of the study will be approximately 12 months.

While on study, in addition to measuring their weight and blood pressure via the Bluetooth devices, the study team asks that participants also have their blood collected. Participants will have to go to their local LabCorp facility to have blood drawn at baseline visit, 3 months, 6 months, and 12 months. Participants will also be asked to complete surveys via their email. Surveys will ask about participant's current medications and ask them to score their overall health at that time.

This ClinicalTrials.gov record is specific to the second part of the study.

Interventions

  • Other TOPS Classes
    Attend Dietician-Led Sessions

Primary outcome measures

  • Number of invitations sent through the electronic health record to get 25 individuals consented to the study [Time frame: 1-2 months]
  • Percentage of TOPS group session attendance [Time frame: 12 months]
  • Number of participants who stay in the study [Time frame: 3 months, 6 months, 9 months, 12 months]
  • Number of participants who transition from the initiation phase to the maintenance phase [Time frame: 12 months]
  • Number of participants who continue to transmit weight and BP data once they transition to the maintenance phase [Time frame: 9 months, 12 months]
  • Percent of Weight Loss [Time frame: Up to 12 Months]
Secondary outcome measures (5)
  • Cardiovascular Disease (CVD) risk factors as measured by blood pressure [Time frame: up to 12 months]
  • Cardiovascular Disease (CVD) risk factors as measured by hemoglobin A1c [Time frame: up to 12 months]
  • Cardiovascular Disease (CVD) risk factors as measured by glucose [Time frame: up to 12 months]
  • Percentage of participants who get blood drawn [Time frame: Baseline, 3 months, 6 months,12 months]
  • Quality of Life (QOL) as measured by survey [Time frame: up to 12 months]

Eligibility criteria

Aim 2 Inclusion Criteria:

  • women diagnosed with breast cancer with BMI ≥ 25 kg/m2 after completion of primary therapy (surgery, radiation, adjuvant or neo-adjuvant chemotherapy).

Aim 2 Exclusion Criteria:

  • Those whose oncology providers do not agree with their participation in a weight loss program
  • History of Type II Diabetes Mellitus
  • those participating in another weight loss program
  • those taking a weight loss medication
  • those without smart phones or internet connections or the ability to attend meetings via Zoom

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Duke University — Durham

Identifiers

NCT: NCT06658912 · Pro00116571

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗